Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis
- PMID: 28498059
- DOI: 10.3171/2016.11.JNS161974
Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis
Abstract
OBJECTIVE The available evidence suggests that the clinical benefits of extended resection are limited for chemosensitive tumors, such as primary CNS lymphoma. Oligodendroglioma is generally believed to be more sensitive to chemotherapy than astrocytoma of comparable grades. In this study the authors compare the survival benefit of gross-total resection (GTR) in patients with oligodendroglioma relative to patients with astrocytoma. METHODS Using the Surveillance, Epidemiology, and End Results (SEER) Program (1999-2010) database, the authors identified 2378 patients with WHO Grade II oligodendroglioma (O2 group) and 1028 patients with WHO Grade III oligodendroglioma (O3 group). Resection was defined as GTR, subtotal resection, biopsy only, or no resection. Kaplan-Meier and multivariate Cox regression survival analyses were used to assess survival with respect to extent of resection. RESULTS Cox multivariate analysis revealed that the hazard of dying from O2 and O3 was comparable between patients who underwent biopsy only and GTR (O2: hazard ratio [HR] 1.06, 95% confidence interval [CI] 0.73-1.53; O3: HR 1.18, 95% CI 0.80-1.72). A comprehensive search of the published literature identified 8 articles without compelling evidence that GTR is associated with improved overall survival in patients with oligodendroglioma. CONCLUSIONS This SEER-based analysis and review of the literature suggest that GTR is not associated with improved survival in patients with oligodendroglioma. This finding contrasts with the documented association between GTR and overall survival in anaplastic astrocytoma and glioblastoma. The authors suggest that this difference may reflect the sensitivity of oligodendroglioma to chemotherapy as compared with astrocytomas.
Keywords: 75ST = the time in months at which 25% of the original patient population had died; CI = confidence interval; EOR = extent of resection; Epidemiology; GTR = gross-total resection; HGG = high-grade glioma; HR = hazard ratio; ICD-O-3 = International Classification of Diseases for Oncology-Third Edition; IQR = interquartile range; O2 = WHO Grade II oligodendroglioma; O3 = WHO Grade III oligodendroglioma; PCNSL = primary CNS lymphoma; SEER; SEER = Surveillance; STR = subtotal resection; Surveillance; and End Results; extent of resection; gross-total resection; oligodendroglioma; oncology; survival.
Similar articles
-
Effect of Gross Total Resection in World Health Organization Grade II Astrocytomas: SEER-Based Survival Analysis.World Neurosurg. 2017 Jul;103:741-747. doi: 10.1016/j.wneu.2017.03.140. Epub 2017 Apr 16. World Neurosurg. 2017. PMID: 28419878
-
Extent of resection and survival for oligodendroglioma: a U.S. population-based study.J Neurooncol. 2019 Sep;144(3):591-601. doi: 10.1007/s11060-019-03261-5. Epub 2019 Aug 12. J Neurooncol. 2019. PMID: 31407129
-
Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis.J Neurooncol. 2017 May;133(1):173-181. doi: 10.1007/s11060-017-2430-z. Epub 2017 Apr 24. J Neurooncol. 2017. PMID: 28439777 Review.
-
Superior Efficacy of Gross Total Resection in Anaplastic Astrocytoma Patients Relative to Glioblastoma Patients.World Neurosurg. 2016 Jun;90:186-193. doi: 10.1016/j.wneu.2016.02.078. Epub 2016 Feb 24. World Neurosurg. 2016. PMID: 26924115
-
Surgical outcomes of pediatric spinal cord astrocytomas: systematic review and meta-analysis.J Neurosurg Pediatr. 2018 Oct;22(4):404-410. doi: 10.3171/2018.4.PEDS17587. Epub 2018 Jul 20. J Neurosurg Pediatr. 2018. PMID: 30028275
Cited by
-
Treatment Options for IDH-Mutant Malignant Gliomas.Curr Treat Options Oncol. 2024 Dec;25(12):1594-1604. doi: 10.1007/s11864-024-01280-7. Epub 2024 Nov 29. Curr Treat Options Oncol. 2024. PMID: 39612163 Review.
-
Intraoperative detection of IDH-mutant glioma using fluorescence lifetime imaging.J Biophotonics. 2023 Apr;16(4):e202200291. doi: 10.1002/jbio.202200291. Epub 2022 Dec 23. J Biophotonics. 2023. PMID: 36510639 Free PMC article.
-
A Population-Based Study of Treatment and Survival in Older Glioma Patients.JNCI Cancer Spectr. 2022 Jan 5;6(1):pkac010. doi: 10.1093/jncics/pkac010. JNCI Cancer Spectr. 2022. PMID: 35699501 Free PMC article.
-
Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.Eur Radiol. 2024 Feb;34(2):1376-1387. doi: 10.1007/s00330-023-10125-0. Epub 2023 Aug 23. Eur Radiol. 2024. PMID: 37608093
-
An expanded role for surgery in grade 3 1p/19q co-deleted oligodendroglioma.Neurooncol Adv. 2023 Apr 21;5(1):vdad046. doi: 10.1093/noajnl/vdad046. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37215951 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical